- Home
- NEO vs BBOT Comparison
NEO vs BBOT Comparison
Compare NEO & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEO
- BBOT
- Stock Information
- Founded
- NEO 2001
- BBOT 2016
- Country
- NEO United States
- BBOT United States
- Employees
- NEO N/A
- BBOT N/A
- Industry
- NEO Precision Instruments
- BBOT Biotechnology: Pharmaceutical Preparations
- Sector
- NEO Health Care
- BBOT Health Care
- Exchange
- NEO Nasdaq
- BBOT Nasdaq
- Market Cap
- NEO 1.2B
- BBOT 1.1B
- IPO Year
- NEO 1999
- BBOT N/A
- Fundamental
- Price
- NEO $10.60
- BBOT $12.34
- Analyst Decision
- NEO Buy
- BBOT Strong Buy
- Analyst Count
- NEO 10
- BBOT 4
- Target Price
- NEO $12.56
- BBOT $24.75
- AVG Volume (30 Days)
- NEO 3.0M
- BBOT 133.6K
- Earning Date
- NEO 10-28-2025
- BBOT 11-12-2025
- Dividend Yield
- NEO N/A
- BBOT N/A
- EPS Growth
- NEO N/A
- BBOT N/A
- EPS
- NEO N/A
- BBOT N/A
- Revenue
- NEO $709,162,000.00
- BBOT N/A
- Revenue This Year
- NEO $10.74
- BBOT N/A
- Revenue Next Year
- NEO $9.85
- BBOT N/A
- P/E Ratio
- NEO N/A
- BBOT N/A
- Revenue Growth
- NEO 10.10
- BBOT N/A
- 52 Week Low
- NEO $4.72
- BBOT $8.50
- 52 Week High
- NEO $19.12
- BBOT $14.04
- Technical
- Relative Strength Index (RSI)
- NEO 59.78
- BBOT N/A
- Support Level
- NEO $9.89
- BBOT N/A
- Resistance Level
- NEO $10.44
- BBOT N/A
- Average True Range (ATR)
- NEO 0.52
- BBOT 0.00
- MACD
- NEO -0.03
- BBOT 0.00
- Stochastic Oscillator
- NEO 67.92
- BBOT 0.00
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
About BBOT BridgeBio Oncology Therapeutics Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.